Lataa...
Identification of a Novel MPRIP-ROS1 Fusion and Clinical Efficacy of Crizotinib in an Advanced Lung Adenocarcinoma Patient: A Case Report
OBJECTIVE: ROS1 fusions have been identified in 1–2% of non-small-cell lung cancer (NSCLC) patients; they are validated as a driver of carcinogenesis and could be subjected to inhibition by crizotinib. However, previous studies suggested a variable progression-free survival (PFS) ranging from 9.1 to...
Tallennettuna:
| Julkaisussa: | Onco Targets Ther |
|---|---|
| Päätekijät: | , , , , , , , , , |
| Aineistotyyppi: | Artigo |
| Kieli: | Inglês |
| Julkaistu: |
Dove
2020
|
| Aiheet: | |
| Linkit: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7568639/ https://ncbi.nlm.nih.gov/pubmed/33116618 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/OTT.S270961 |
| Tagit: |
Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!
|